Conducting Research on Subjects Diagnosed with, or at Risk for, Cancer

Conducting Research on Subjects Diagnosed with, or at Risk for, Cancer

As the home to the Helen Diller Family Comprehensive Cancer Center (HDFCCC), designated and supported by the National Cancer Institute (NCI), all protocols designed to conduct research on subjects diagnosed with, or at risk for, cancer at UCSF are subject to additional review and monitoring processes not required of non-cancer protocols.  Therefore, in addition to requiring review by the UCSF IRB, your cancer-related protocols are subject to:

Initial and continuing review by at least one Site Committee*

Initial and continuing review by the Protocol Review Committee (PRC)*

Monitoring, auditing and dose escalation approval of investigator-initiated** and NCI Cooperative Group trials by the Data and Safety Monitoring Committee (DSMC)

Accrual data entry in UCSF's Clinical Trials Monitoring System OnCore

Please see above links for further information.

Such protocols may also be eligible to receive centralized support from the Clinical Research Support Office (CRSO).

*  Initial approval must precede initial UCSF IRB approval.

** Can include studies written by an investigator at another institution.

---

Other Clinical Research Resources

• Research Administration Resources
• Cancer Therapy Evaluation Program (CTEP)
• UCSF IRB
• UCSF Office of Clinical Trials Activation